These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 6434377)

  • 1. Supply and need of factor VIII concentrates.
    Britten A; Etzel F; Ala F; Carman C; Smit Sibinga C
    Haematologia (Budap); 1983; 16(1-4):109-20. PubMed ID: 6434377
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Factor VIII usage in the Wisconsin Hemophilia Program; factor VIII usage in hemophilia.
    Lange D; Lazerson J
    Wis Med J; 1982 Feb; 81(2):28-31. PubMed ID: 6803446
    [No Abstract]   [Full Text] [Related]  

  • 3. [Preparation and use of factor VIII concentrates in hemophilia].
    Vilar JM; Ortega F; Martin-Arias DM; Vazquez J; Navarro JL
    Sangre (Barc); 1969; 14(1):57-64. PubMed ID: 5792112
    [No Abstract]   [Full Text] [Related]  

  • 4. Incidence of factor VIII inhibitor development in hemophilia A patients treated with less pure plasma derived concentrates.
    de Biasi R; Rocino A; Papa ML; Salerno E; Mastrullo L; De Blasi D
    Thromb Haemost; 1994 May; 71(5):544-7. PubMed ID: 8091377
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rationale and indications for continuous infusion of antihemophilic factor (factor VIII).
    Goldsmith JC
    Blood Coagul Fibrinolysis; 1996 Mar; 7 Suppl 1():S3-6. PubMed ID: 8735789
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Production of factor VIII preparations and their use in the substitution therapy of hemophilia A].
    Gaerisch F; Stein P
    Z Gesamte Inn Med; 1982 Oct; 37(19):641-4. PubMed ID: 6817530
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recombinant factor VIII in hemophilia A: the Canadian experience.
    Blanchette VS
    Blood Coagul Fibrinolysis; 1997 Aug; 8 Suppl 1():S33-9. PubMed ID: 9351535
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Continuous infusion of factor VIII for surgery and major bleeding.
    Hay CR; Doughty HI; Savidge GF
    Blood Coagul Fibrinolysis; 1996 Mar; 7 Suppl 1():S15-9. PubMed ID: 8735792
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The clinical use of porcine factor VIII.
    Kernoff PB
    Prog Clin Biol Res; 1990; 324():47-56. PubMed ID: 2106692
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hemophilia factor VIII therapy. Immunological tolerance. A clinical perspective.
    White GC; Greenwood R; Escobar M; Frelinger JA
    Haematologica; 2000 Oct; 85(10 Suppl):113-6. PubMed ID: 11187862
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [in vivo reappearance of injected cryoprecopitate (factor VIII concentrates) in patients with hemophilia A].
    Kuble M; Wegner H; Cron D
    Z Gesamte Inn Med; 1973 Oct; 28(20):608-14. PubMed ID: 4767194
    [No Abstract]   [Full Text] [Related]  

  • 12. Prophylaxis in haemophilic children.
    Liesner RJ
    Blood Coagul Fibrinolysis; 1997 Aug; 8 Suppl 1():S7-10. PubMed ID: 9351529
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The treatment of classical hemophilia with factor 8 concentrates.
    Waterbury L; Frenkel EP
    Clin Anesth; 1968; 3():288-97. PubMed ID: 4902367
    [No Abstract]   [Full Text] [Related]  

  • 14. Factors affecting choice of hemostatic agent for the hemophilia patient with an inhibitor antibody.
    Monahan PE; Aledort LM;
    Am J Hematol; 2004 Dec; 77(4):346-50. PubMed ID: 15558804
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of plasma-derived factor VIII/von Willebrand factor concentrates in the treatment of hemophilia A patients.
    Auerswald G; Spranger T; Brackmann HH
    Haematologica; 2003 Jun; 88(6):EREP05. PubMed ID: 12826531
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Products for the treatment of hemophilia A and B prepared by ion exchange chromatography.
    Sultan Y; Boyeldieu D; Stieltjes N
    Nouv Rev Fr Hematol (1978); 1994; 36 Suppl 1():S59-60. PubMed ID: 8177717
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of hemophilia with factor 8 concentrates.
    Dallman PR; Pool JG
    N Engl J Med; 1968 Jan; 278(4):199-202. PubMed ID: 5711341
    [No Abstract]   [Full Text] [Related]  

  • 18. Development and present status of concentrate therapy for hemophilia and von Willebrand's disease.
    Brinkhous KM
    Wien Klin Wochenschr; 1982 Oct; 94(19):509-14. PubMed ID: 6818773
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hemostasis. II. The use of factor VIII concentrates in the therapy of hemophilia.
    Davis RB
    Nebr State Med J; 1971 Jun; 56(6):219-24. PubMed ID: 4253029
    [No Abstract]   [Full Text] [Related]  

  • 20. Lower doses of factor VIII for hemophilia.
    Penner JA; Kelly PE
    N Engl J Med; 1977 Aug; 297(7):401. PubMed ID: 876340
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.